The aim of this project is to explore the 3D printing of peadiatric medicines. 3D printing technology enables the creation of medications with a wide range of dosages, shapes, flavors, and drug combinations, all customized to meet the unique needs of individual patients and specific disease conditions. Once the optimal formulations have been developed, the 3D printed medicines will undergo clinical trials for testing.
We will study compounding medication by 3D printing technology. In this way personalized medication will become more accessable.
First formulation studies will be executed in order to provide a stable production process. After which, the use of 3D printing will be introduced in the clinical setting. Finally, the printed medication will be tested by a clinical trial.
We aim to develop methods to radiolabel orally inhaled drug products, allowing us to more accurately determine lung deposition through imaging techniques.
My research focuses on the occurence of nocebo-effects in statin-intolerant. We try to identify patients who are statin-intolerant and that suffer from these effects. We hope that by identifying patients affected by the nocebo effect and allowing them to experientially understand its impact through an N=1 study design, they will experience fewer side effects from their statin treatment. This may help prevent the need to switch to expensive PCSK9 inhibitors.
Cost benefit analysis clinical medication reviews. Follow up of interventions from clinical pharmacists. Medication information needs of hospitalized patients.